# Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation

> **NCT03468140** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- End Stage Liver Disease

## Interventions

- **DRUG:** Eculizumab
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT03468140
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to recruit due to COVID 19
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468140, "Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03468140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*